HOLZKIRCHEN, Germany, Jan. 16, 2018 /PRNewswire/ — Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for…
